Cover Image
市場調查報告書

支氣管擴張症:開發平台分析

Bronchiectasis - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 192510
出版日期 內容資訊 英文 84 Pages
訂單完成後即時交付
價格
Back to Top
支氣管擴張症:開發平台分析 Bronchiectasis - Pipeline Review, H2 2016
出版日期: 2016年10月26日 內容資訊: 英文 84 Pages
簡介

支氣管擴張症是由於呼吸道損傷造成的疾病,會引起呼吸道擴大,鬆弛和疤痕化。支氣管擴張症也常是造成感染疾病或呼吸道壁受傷,或是阻礙黏液消除 之其他疾病的原因。症狀有咯血、口臭、復發性肺感染疾病、喘鳴及呼吸急促等。治療方法有抗生素,支氣管擴張劑及皮質類固醇等。

本報告涵括全球支氣管擴張症治療藥的開發平台,提供目前開發平台狀況和最新趨勢,藥物簡介,主要企業及開發中的產品評估等,為您概述為以下內容。

目錄

簡介

  • 分析範圍

支氣管擴張症概要

治療藥的開發

  • 支氣管擴張症轉動開發中產品:概要
  • 支氣管擴張症轉動開發中產品:比較分析

支氣管擴張症:開發中的治療藥 - 各企業

支氣管擴張症:開發中的治療藥 - 大學·研究機關別

支氣管擴張症:開發中產品概況

  • 後期階段的產品
  • 臨床實驗階段的產品
  • 初期階段的產品

支氣管擴張症:開發中的產品 - 各企業

支氣管擴張症:開發中的產品 - 大學·研究機關別

支氣管擴張症:治療藥的開發企業

  • Alitair Pharmaceuticals, Inc.
  • Bayer AG
  • Grifols, S.A.
  • Kamada Ltd.
  • Nostrum Pharmaceuticals, LLC
  • Pulmatrix, Inc.
  • Recipharm AB
  • Savara Inc.
  • Serendex Pharmaceuticals A/S
  • Therabron Therapeutics, Inc.
  • Vertex Pharmaceuticals Incorporated

支氣管擴張症:治療藥的評估

  • 單劑治療藥
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • alpha-1 proteinase inhibitor (human) second generation
  • ALT-09
  • ARD-3150
  • BAY-858501
  • CG-1011
  • ciprofloxacin
  • dapsone
  • doxofylline
  • erdosteine
  • Leukotriene B4
  • levofloxacin
  • molgramostim
  • PB-01
  • vancomycin hydrochloride
  • VX-371
    • 產品概要
    • 作用機制
    • R&D的進展

最新的開發平台趨勢

暫停中的計劃

開發中止的產品

產品開發里程碑

  • 關注的新聞·新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8587IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Bronchiectasis - Pipeline Review, H2 2016, provides an overview of the Bronchiectasis (Respiratory) pipeline landscape.

Bronchiectasis is a chronic condition where the walls of the bronchial tubes are permanently damaged. These damage allow bacteria and mucus to build up in lungs. Bronchiectasis is divided into two categories cystic fibrosis (CF) bronchiectasis and non-CF bronchiectasis. Symptoms include chronic coughing, shortness of breath, chest pain, fatigue, weight loss and fever. Causes of bronchiectasis include inhaling foreign object, cystic fibrosis, GERD and weakness in immune system. Treatment includes antibiotics to fight infection, bronchodilators, expectorants and mucolytic agents.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Bronchiectasis - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Bronchiectasis (Respiratory), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Bronchiectasis (Respiratory) pipeline guide also reviews of key players involved in therapeutic development for Bronchiectasis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I and Preclinical stages are 1, 1, 3, 4 and 3 respectively for Bronchiectasis.

Bronchiectasis (Respiratory) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Bronchiectasis (Respiratory).
  • The pipeline guide reviews pipeline therapeutics for Bronchiectasis (Respiratory) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Bronchiectasis (Respiratory) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Bronchiectasis (Respiratory) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Bronchiectasis (Respiratory)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Bronchiectasis (Respiratory).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Bronchiectasis (Respiratory) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Bronchiectasis Overview
  • Therapeutics Development
    • Pipeline Products for Bronchiectasis - Overview
  • Bronchiectasis - Therapeutics under Development by Companies
  • Bronchiectasis - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Bronchiectasis - Products under Development by Companies
  • Bronchiectasis - Companies Involved in Therapeutics Development
    • Alitair Pharmaceuticals, Inc.
    • Bayer AG
    • Grifols, S.A.
    • Insmed Incorporated
    • Kamada Ltd.
    • Polyphor Ltd.
    • Raptor Pharmaceutical Corp.
    • Recipharm AB
    • Savara Inc.
    • Vertex Pharmaceuticals Incorporated
  • Bronchiectasis - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • alpha-1 proteinase inhibitor (human) second generation - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • amikacin sulfate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ARD-3150 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ciprofloxacin hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • doxofylline - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • erdosteine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Leukotriene-B4 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • levofloxacin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • POL-6014 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • POL-7080 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • vancomycin hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VX-371 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Bronchiectasis - Dormant Projects
  • Bronchiectasis - Discontinued Products
  • Bronchiectasis - Product Development Milestones
    • Featured News & Press Releases
      • Oct 18, 2016: Bayer to Present Data in Non-Cystic Fibrosis Bronchiectasis at the 2016 Annual Meeting of the American College of Chest Physicians
      • Sep 22, 2016: Aradigm Announces Last Patient Dosing Visit in ORBIT-3 and ORBIT-4 Phase 3 Studies of Pulmaquin in Non-Cystic Fibrosis Bronchiectasis Patients
      • Mar 17, 2016: Aradigm Announces Decision for Centralized Review of Pulmaquin by the European Medicines Agency
      • Mar 16, 2016: Raptor Announces Qualified Infectious Disease Product Designation for MP-376, Inhaled Levofloxacin
      • Jan 05, 2016: Aradigm to Host Corporate Update Conference Call on January 6
      • Oct 13, 2015: Aradigm Completes Enrollment in the Second Phase III Study of Pulmaquin in Non-Cystic Fibrosis Bronchiectasis
      • Sep 22, 2015: Aradigm Completes Enrollment in Phase III Study of Pulmaquin in Non-Cystic Fibrosis Bronchiectasis (ORBIT-4)
      • Apr 16, 2015: Aradigm to Host Key Opinion Leader Breakfast and Webcast on April 23 in New York City
      • Jan 14, 2015: Aradigm Granted Key Composition of Matter Patents for Pulmaquin in Europe and Australia
      • Nov 24, 2014: FDA Grants QIDP Designation to Bayer's Ciprofloxacin Dry Powder for Inhalation
      • Sep 04, 2014: FDA Grants Fast Track Designation to Aradigm's Pulmaquin for Non-Cystic Fibrosis Bronchiectasis
      • Jun 23, 2014: Aradigm Corporation Announces the Dosing of the First Patient in Phase III Study of Pulmaquin in Non-Cystic Fibrosis Bronchiectasis (ORBIT-4)
      • Jun 03, 2014: Aradigm Receives $5 Million Milestone For Dosing of the First Patient in Phase III Study of Pulmaquin in Non-Cystic Fibrosis Bronchiectasis
      • May 20, 2014: FDA Grants QIDP Designation to Aradigm's Inhaled Antibiotic
      • Apr 28, 2014: Erdosteine Received Orphan Drug Status by the FDA
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Bronchiectasis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Bronchiectasis - Pipeline by Alitair Pharmaceuticals, Inc., H2 2016
  • Bronchiectasis - Pipeline by Bayer AG, H2 2016
  • Bronchiectasis - Pipeline by Grifols, S.A., H2 2016
  • Bronchiectasis - Pipeline by Insmed Incorporated, H2 2016
  • Bronchiectasis - Pipeline by Kamada Ltd., H2 2016
  • Bronchiectasis - Pipeline by Polyphor Ltd., H2 2016
  • Bronchiectasis - Pipeline by Raptor Pharmaceutical Corp., H2 2016
  • Bronchiectasis - Pipeline by Recipharm AB, H2 2016
  • Bronchiectasis - Pipeline by Savara Inc., H2 2016
  • Bronchiectasis - Pipeline by Vertex Pharmaceuticals Incorporated, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Bronchiectasis - Dormant Projects, H2 2016
  • Bronchiectasis - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Bronchiectasis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top